| Featured Articles |
 |
A Treatment Timeline
POZ Magazine | January 17, 2023
|
|
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Gilead | December 22, 2022
|
|
FDA Approves SUNENCA (lenacapavir) for Adults with Limited Treatment Options
FDA | December 22, 2022
|
|
POZ | December 8, 2022 |
|
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel
JAMA. 2022; doi:10.1001/jama.2022.22246. [epublished online December 1, 2022] |
|
Exciting alternatives: An overview of long-acting HIV treatment, prevention
Healio | October 2022 |
|
American Academy of HIV Medicine | August 22, 2022 |
|
Long-acting Agent Resource Center website
HIV LAA | August 2022 |
|
2022 HIV Drug Chart
POZ | June 27, 2022 |
|
12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry
Sintered Filter | May 10, 2022 |
|
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
HIV.gov | January 20, 2022 |
|
Updates in the Pipeline of HIV Therapy
Infectious Disease Special Edition | January 14, 2022 |
| |
|
|
| News Updates |
|
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.
|
|
FDA approves Sunlenca for treatment-resistant HIV
Medical Xpress | December 29, 2022
|
|
Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak
Am J Ophthalmol Case Rep. 2022 Dec 13;101779. doi: 10.1016/j.ajoc.2022.101779.
|
|
ContagionLive | December 9, 2022 |
|
Antiretroviral Drugs for HIV Clinical Practice Guidelines (IAS,2022)
Medscape | December 9, 2022 |
|
Do Antidepressants Make HIV Meds Less Effective?
Plus Magazine | December 9, 2022 |
|
kpbs.org | December 8, 2022 |
|
Toolkit: Long-Acting Injectables in HIV Treatment
TargetHIV | November 15, 2022
|
|
Fostemsavir Plus Optimized Background Therapy May Be Viable for MDR HIV |
|
Dolutegravir Effectively Suppresses HIV in Pregnant Women
Contagion Live | November 2, 2022 |
|
FDA reports shortages of amoxicillin (November 1, 2022)
The Hill | November 1, 2022 |
|
HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV
Infectious Disease Advisor | October 28, 2022 |
|
Tybost (Cobicistat) - Oral: Uses, Side Effects, Dosages, Interactions
Verywell Health | October 28, 2022 |
|
European Medicines Agency Validates Viiv Healthcare's Marketing Authorisation Application For Cabotegravir Long-Acting Injectable For HIV Prevention
ViiV Healthcare | October 28, 2022 |
|
Gilead's latest Biktarvy data offers hope to HIV patients
PMLiVE | October 25, 2022 |
|
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1. |
|
Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS
Contagion Live | October 21, 2022 |
|
Long-Term Biktarvy Resulted in High Rates of Viral Suppression
Infectious Disease Special Edition | October 20, 2022 |
| |
|
|
